| Status | In progress |
| Process | STA 2018 |
| ID number | 1304 |
Provisional Schedule
| Appraisal consultation: 1 | 25 June 2020 - 23 July 2020 |
| Committee meeting: 2 | 09 September 2020 |
| Expected publication | 18 November 2020 |
Project Team
| Project lead | Jo Ekeledo |
Email enquiries
- If you have any queries please email TACommE@nice.org.uk
| Evidence Review Group / Assessment Group | Warwick Evidence, Warwick Medical School, University of Warwick |
Consultees
| Companies sponsors | Novartis (siponimod) |
| Others | Department of Health and Social Care |
| NHS England | |
| Welsh Government | |
| Patient carer groups | Multiple Sclerosis Society |
| Multiple Sclerosis Trust | |
| Professional groups | Association of British Neurologists |
| Royal College of Physicians | |
| UK Clinical Pharmacy Association | |
| UK Multiple Sclerosis Specialist Nurse Association |
Commentators
| Comparator companies | Novartis (interferon beta 1b) |
| Bayer (interferon beta 1b) - (confidentiality agreement not signed, not participating) | |
| Biogen (dimethyl fumarate, interferon beta 1a) | |
| Merck (interferon beta 1a) (confidentiality agreement not signed, not participating) | |
| Mylan (glatiramer acetate) (confidentiality agreement not signed, not participating) | |
| Roche (ocrelizumab) | |
| Sanofi Genzyme (teriflunomide) | |
| Teva (glatiramer acetate(confidentiality agreement not signed, not participating) | |
| General commentators | All Wales Therapeutics and Toxicology Centre |
| British National Formulary | |
| Department of Health, Social Services and Public Safety for Northern Ireland | |
| Healthcare Improvement Scotland | |
| Scottish Medicines Consortium | |
| Welsh Health Specialised Services Committee |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 17 June 2020 | Siponimod for treating secondary progressive multiple sclerosis [ID1304] has now been rescheduled into the work programme . The topic webpage will be updated with the new timelines and expected publication date in due course. |
| 02 April 2020 | Topic update: this appraisal has not been defined as therapeutically critical (please follow the link titled rapid guidelines and evidence summaries within the yellow banner at the top of the page for information on recent changes to the way we work). The appraisal will therefore be paused. At this stage, we are unable to provide alternative timelines as to when the appraisal may be re-started but we will provide updates as and when this information becomes clear. |
| 12 March 2020 | Committee meeting: 1 |
| 16 July 2019 | Invitation to participate |
| 16 July 2019 | In progress. Appraisal has been referred to NICE. |
| 20 November 2018 - 18 December 2018 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
For further information on how we develop guidance, please see our page about NICE technology appraisal guidance